SEER
Seek Inc. is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. The Company\'s Proteograph is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. The Company\'s designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers.
Seer, Inc. (SEER) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B (3.3) | C (2.2) | B (3.3) | B- (2.9) | C+ (2.6) | B- (2.9) |
| 2026-11-07 | B (3.4) | C- (1.9) | C+ (2.8) | C+ (2.8) | C+ (2.7) | C+ (2.7) |
| 2026-10-31 | B (3.3) | D+ (1.8) | C+ (2.8) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-24 | B (3.3) | D+ (1.8) | C+ (2.8) | C+ (2.5) | C+ (2.6) | C+ (2.6) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe